B
TEVA icon

Birchbrook’s Teva Pharmaceuticals TEVA Stock Holding History

Birchbrook’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-45
Closed -$635 – 281
2024
Q1 		$635 Hold
45
– – ﹤0.01% 260
2023
Q4 		$470 Buy
+45
New +$420 ﹤0.01% 293

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Birchbrook's TEVA Position: Q2 2024 in Review

Birchbrook sold out of Teva Pharmaceuticals (TEVA) in Q2 2024, closing a stake of 45 shares — an estimated $635 sold.

Birchbrook first reported a position in TEVA in Q4 2023 and held it in 2 quarters. The position peaked at $635 in Q1 2024. 533 funds tracked by Wall St. Rank hold TEVA as of Q2 2024.

  • Birchbrook reported no remaining Teva Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Birchbrook sold 45 Teva Pharmaceuticals shares in Q2 2024, an estimated $635.
  • Birchbrook first reported a position in Teva Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Birchbrook's Teva Pharmaceuticals position peaked at $635 in Q1 2024.
  • 533 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2024.

Based on Birchbrook's 13F filing for Q2 2024, filed 10 Jun 2025.